Clinical Trials
12
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
- Conditions
- Glaucoma
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- iSTAR Medical
- Target Recruit Count
- 30
- Registration Number
- NCT07009236
- Locations
- 🇭🇳
Los Robles Vision d/b/a Centro Oftalmológico Robles, Santa Rosa de Copán, Honduras
🇬🇧Colchester General Hospital, Colchester, United Kingdom
🇬🇧St Thomas' Hospital, London, United Kingdom
MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract
- Conditions
- CataractPrimary Open-angle Glaucoma
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- iSTAR Medical
- Target Recruit Count
- 30
- Registration Number
- NCT05432245
- Locations
- 🇵🇦
Panama Eye Center, Panama City, Panama
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
🇬🇧East Suffolk and North Essex NHS Foundation Trust - Colchester General Hospital, Colchester, Essex, United Kingdom
STAR-LIFE: a Post-market Registry on MINIject
- Conditions
- Open Angle Glaucoma
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- iSTAR Medical
- Target Recruit Count
- 750
- Registration Number
- NCT05269680
- Locations
- 🇨🇭
Universitatsklinik fur Augenheilkunde Inselspital, Bern, Switzerland
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
- Conditions
- Glaucoma
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- iSTAR Medical
- Target Recruit Count
- 975
- Registration Number
- NCT05024695
- Locations
- 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
🇺🇸Vold Vision, Fayetteville, Arkansas, United States
🇺🇸Beverly Hills Institute of Ophthalmology, Beverly Hills, California, United States
MINIject Global Long-Term Follow-up Study
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- iSTAR Medical
- Target Recruit Count
- 300
- Registration Number
- NCT04524416
- Locations
- 🇨🇴
Clinica Oftalmologica del Caribe, Barranquilla, Colombia
🇫🇷Center Hospotalier Universitaire Genoble Alpes, Grenoble, France
🇫🇷Hopital de la Croix-Rousse, Lyon, France
- Prev
- 1
- 2
- 3
- Next
News
MINIject Shows Sustained 5-Year Efficacy in Glaucoma Treatment, iSTAR Medical Reports
• The STAR-GLOBAL trial demonstrated MINIject maintained a significant 38% reduction in intraocular pressure through five years, with 83% of patients achieving >20% IOP reduction from baseline. • Over 5,000 patients worldwide have received the supraciliary MIGS device since its commercial launch, with data confirming a favorable long-term safety profile including corneal health. • iSTAR Medical will continue independent development of MINIject following the conclusion of its partnership with AbbVie, with FDA submission targeted for 2028.